pf-03463275
Small moleculeexperimental
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2007 (NCT00567203)
Timeline
Indications
Mechanism of action
- Glycine transporter 1INHIBITOR
SLC6A9 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CN1C[C@@H]2[C@H](C1)[C@H]2CN(Cc1ccc(F)c(Cl)c1)C(=O)c1cn(C)cn1- Mol. weight
- 376.86 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL563251 ↗
Also known as
- 1-methyl-1h-imidazole-4-carboxylic acid (3-chloro-4-fluoro-benzyl)-(3-methyl-3-aza-bicyclo(3.1.0) hex-6-ylmethyl)amide
- pf-03463275
- pf-03463275
- pf-03463275
- pf-03463275
- pf-3463275
- pf-3463275
- pf-3463275
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01911676 | Phase 2 | Aug 1, 2013 | Yale University |
| NCT01159626 | Phase 1 | Jul 1, 2010 | Pfizer |
| NCT00977522 | Phase 2 | Nov 1, 2009 | Pfizer |
| NCT00567203 | Phase 1 | Nov 1, 2007 | Pfizer |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pfizer | For profit | 3 | 3 | 2 | 2007 |
| Yale University | Academic/Hospital | 1 | 1 | 1 | 2013 |
2 organizations
Page 1 / 1